Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Revenue - Other
Ratios

Mereo BioPharma (MREO) Accumulated Depreciation & Amortization (2022 - 2025)

Historic Accumulated Depreciation & Amortization for Mereo BioPharma (MREO) over the last 4 years, with Q3 2025 value amounting to $1.0 million.

  • Mereo BioPharma's Accumulated Depreciation & Amortization rose 861.0% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 861.0%. This contributed to the annual value of $949000.0 for FY2024, which is 1862.5% up from last year.
  • Latest data reveals that Mereo BioPharma reported Accumulated Depreciation & Amortization of $1.0 million as of Q3 2025, which was up 861.0% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma's Accumulated Depreciation & Amortization peaked at $1.1 million during Q2 2025, and registered a low of $736000.0 during Q4 2022.
  • For the 4-year period, Mereo BioPharma's Accumulated Depreciation & Amortization averaged around $926111.1, with its median value being $949000.0 (2024).
  • Within the past 5 years, the most significant YoY rise in Mereo BioPharma's Accumulated Depreciation & Amortization was 2656.78% (2025), while the steepest drop was 861.0% (2025).
  • Mereo BioPharma's Accumulated Depreciation & Amortization (Quarter) stood at $736000.0 in 2022, then increased by 8.7% to $800000.0 in 2023, then rose by 18.62% to $949000.0 in 2024, then increased by 10.33% to $1.0 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $1.0 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.0 million for Q1 2025.